Childhood Vaccination Rates Fall Again, Exemptions Rise on Cusp of New School Year: CDC Annual Update
August 01, 2025

Only 92.5% of kindergartners received the recommended 2-shot MMR series in 2024-25 and rates were similarly low for DTaP and polio, according to the CDC.

Vaccine Hesitancy: Communication Strategies for Primary Care That Preserve Trust
August 01, 2025

Amesh Adalja, MD, infectious disease physician, outlines effective communication strategies that respect patient concerns while reinforcing physician credibility.

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia
August 01, 2025

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025
August 01, 2025

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.

Tirzepatide Proves Noninferiority With Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off
August 01, 2025

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

Nonmedical Exemptions for Vaccines for Children Should be Eliminated: American Academy of Pediatrics
August 01, 2025

The AAP acknowledges challenges for families but emphasizes mandatory vaccination as crucial for safe school environments.

New Option for Chronic Hand Eczema Gets FDA Green Light: Daily Dose
August 01, 2025

Your daily dose of the clinical news you may have missed.

New Data Highlight Significant Challenges to Managing CAH: Daily Dose
August 01, 2025

Your daily dose of the clinical news you may have missed.

Amesh Adalja, MD, on How to Defuse Vaccine Safety Concerns Without Derailing the Visit
July 31, 2025

Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.

FDA Grants Fast Track Designation to Rezpegaldesleukin for Alopecia Areata
July 31, 2025

FDA grants Fast Track designation to rezpegaldesleukin for severe alopecia areata, highlighting its potential to meet critical treatment needs.